版本:
中国

BRIEF-Protalix announces FDA investigational new drug clearance commence once-monthly dosing study of pegunigalsidase

May 9 Protalix Biotherapeutics Inc:

* Protalix announces FDA investigational new drug clearance to commence once-monthly dosing study of pegunigalsidase alfa (prx-102) for the treatment of fabry disease

* Protalix Biotherapeutics Inc- study planned to commence in Q3 of 2017

* Says study planned to commence in Q3 of 2017

* Says plans to enroll up to 30 fabry patients currently treated with an approved enzyme replacement therapy

* Says safety and efficacy evaluation will occur at twelve months with additional long term follow-up Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐